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Purpose—Albumin-bound paclitaxel, ABI-007 (Abraxane ®), has a different toxicity profile
than solvent-based paclitaxel, including a lower rate of severe neutropenia. The combination of
ABI-007 and carboplatin may have significant activity in a variety of tumor types including non-
small and small cell lung cancer, ovarian cancer, and breast cancer. The purpose of this study was
to determine the maximum tolerated dose (MTD) of ABI-007, on three different schedules in
combination with carboplatin.
Methods—Forty-one patients with solid tumors were enrolled, and received ABI-007 in
combination with carboplatin AUC of 6 on day 1. Group A received ABI-007 at doses ranging
from 220 to 340 mg/m2 on day 1 every 21 days; group B received ABI-007 at 100 or 125 mg/m2
on days 1, 8, and 15 every 28 days; and group C received ABI-007 125 or 150 mg/m2 on days 1
and 8 every 21 days. Dose-limiting toxicities were assessed after the first cycle. Doses were
escalated in cohorts of three to six patients. Fifteen patients participated in a pharmacokinetic
study investigating the effects of the sequence of infusion. ABI-007 was infused first followed by
carboplatin in cycle 1, and vice versa in cycle 2.
Results—The MTD of ABI-007 in combination with carboplatin was 300, 100, and 125 mg/m2
in groups A, B, and C, respectively. Myelosuppression was the primary dose limiting toxicity. No
unexpected or new toxicities were reported. Sequence of infusion did not affect either the
pharmacokinetics of ABI-007 or the degree of neutropenia. Responses were seen in melanoma,
lung, bladder, esophageal, pancreatic, breast cancer, and cancer of unknown primary.
Conclusions—The recommended dose for phase II studies of ABI-007 in combination with
carboplatin (AUC of 6) is 300, 100, 125 mg/m2 for the schedules A, B, and C, respectively. The
combination of ABI-007 and carboplatin is well tolerated and active in this heavily pretreated
patient population.
Keywords
Dose-limiting toxicity; Maximum tolerated dose; Melanoma; Non-small-cell lung cancer; Small-
cell lung cancer; Clinical trial
Introduction
Solvent-based paclitaxel has a wide spectrum of activity and is frequently used as a single
agent or in combination with other chemotherapeutic or biologic agents in the treatment of
cancers of the breast, ovary, lung, and head and neck. While highly effective, solvent-based
paclitaxel has several burdensome side effects, including hypersensitivity reactions,
peripheral neuropathy, neutropenia, alopecia, mucositis, arthalgias, myalgias, and mild
nausea [1,2]. Paclitaxel is highly hydrophobic, and commercially available formulations
require polyethoxylated Castor oil as a solvent to allow parenteral administration. The
polyethoxylated Castor oil solvent may be responsible for the hypersensitivity reactions and
the development of neuropathy [3,4]. ABI-007 (Abraxane®, Abraxis BioScience Inc, Los
Angeles, CA) is a solvent-free, albumin-bound paclitaxel that delivers paclitaxel as a
suspension of albumin particles in saline. This formulation does not require premedication
for hypersensitivity reactions, allows for a shorter infusion time (30 min) compared with
solvent-based paclitaxel, and is not associated with hypersensitivity reactions [5].
A phase III clinical trial in patients with metastatic breast cancer compared treatment with
solvent-based paclitaxel (175 mg/m2) versus treatment with ABI-007 (260 mg/m2) every 3
weeks [5]. Patients who were treated with ABI-007 had a statistically significant higher
objective response rates, and longer time to progression compared with patients who were
treated with solvent-based paclitaxel. Patients who were treated with ABI-007 had a
statistically significant lower incidence of grade 4 neutropenia (9 vs. 22%, respectively; P <
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0.001) and a higher rate of grade 3 sensory neuropathy (10 vs. 2%, respectively; P < 0.001)
than patients who were treated with solvent-based paclitaxel.
Carboplatin and solvent-based paclitaxel is a standard therapy for non-small cell lung cancer
(NSCLC), ovarian cancer, and metastatic breast cancer [6–8]. There is significant interest in
investigating the combination of ABI-007 and carboplatin since the combination may have a
lower rate of toxicity and/or greater efficacy than carboplatin and solvent-based paclitaxel in
multiple different types of malignancies. ABI-007 and solvent based paclitaxel have
significant differences in their standard doses and toxicities. There is also the potential for
additive toxicity with the combination of ABI-007 and carboplatin, and safety and
pharmacokinetic data of ABI-007 in combination with carboplatin is not available.
Therefore, we performed a phase I trial to determine the maximum tolerated dose (MTD) of
ABI-007 in combination with carboplatin.
A phase I trial of cisplatin and solvent-based paclitaxel found the sequence of infusion had a
significant impact on the degree of neutropenia [9]. The sequence of cisplatin before
solvent-based paclitaxel had more profound neutropenia than the sequence of solvent-based
paclitaxel before cisplatin. Pharmacokinetic measurements suggested this difference was
related to a 25% lower paclitaxel clearance rates when cisplatin infusion preceded paclitaxel.
By contrast, a phase I trial of carboplatin and solvent-based paclitaxel in 55 chemotherapy-
naïve NSCLC patients investigated the influence of sequence of infusion of solvent-based
paclitaxel and carboplatin, and did not find any sequence-independent pharmacokinetic
interaction [10]. There was no significant difference in the area under of the curve of
carboplatin between the two sequences of infusions. In a separate phase II trial in 40 patients
with gynecologic malignancies the rate of neutropenia was not influenced by the sequence
of administration of carboplatin and solvent-based paclitaxel [11]. Given these observations;
we investigated whether the sequence of administration of ABI-007 and carboplatin had an
effect on the pharmacokinetics of ABI-007 and the degree of neutropenia.
Patients and methods
Patients
Adults with advanced solid tumors, which had progressed on standard therapy or for which
there was no standard therapy, were eligible for inclusion in this study. Eligibility criteria
included an Eastern Cooperative Oncology Group (ECOG) performance status of zero to
two, an absolute neutrophil count (ANC) ≥1.5 × 109 L−1, platelet count ≥100 × 109 L−1,
and hemoglobin concentration ≥8.0 g/dL. Adequate renal function, defined as a serum
creatinine in the normal range or a Cockcroft-Gault calculated creatinine clearance of ≥60
mL/min, and hepatic function, defined as hepatic transaminases ≤2.5 upper limit of normal
and total bilirubin within the normal range, were required. Patients were not eligible if they
had received chemotherapy, radiation therapy, or immunotherapy for treatment of
malignancy within 3 weeks. No limit was set on the number of previous therapies, and
patients with previous exposure to taxanes were eligible for the study. Patients were required
to have evaluable disease by RECIST [12] or disease that was evaluable by tumor markers.
The protocol was approved by the Protocol Review Committee of Lineberger
Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, and the
Institutional Review Board at the University of North Carolina. All patients gave written
informed consent before any study-related procedures were done.
Study design
This was a phase I non-randomized single-center trial that evaluated safety of ABI-007
administered with carboplatin. The primary objective was to determine the maximum
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tolerated dose (MTD) of ABI-007 on three different schedules in combination with
carboplatin. The secondary objectives were to evaluate sequence dependent effects on
toxicity and pharmacokinetics of ABI-007, and to determine the anti-tumor activity of this
combination as assessed by response. The initial study design included three dose levels on
two treatment schedules, groups A and B; however, when no dose-limiting toxicities were
observed in the first three patients at the third dose level in group A, the trial was amended
to include a fourth dose level. The trial was subsequently amended to explore a third
schedule of ABI-007 and carboplatin, group C; however, only two treatment arms were open
simultaneously. Patients were not randomized between the treatment arms, and patients were
enrolled in three patient cohorts alternating between the two open treatment arms. Three
patients were enrolled at a dose level on one arm and after completion of enrollment at that
dose level, the next three patients would be enrolled at a dose level on the alternate arm that
was open at that time. This trial design was used in order to determine the MTD of ABI-007
on multiple schedules within the context of a single trial. The three schedules were evaluated
separately and in parallel, and there is no intent to compare the treatment schedules with
each other.
Patients in group A received carboplatin on day 1 and ABI-007 on day 1 every 21 days;
patients in group B received carboplatin on day 1 and ABI-007 on days 1, 8, and 15 every
28 days; and patients in group C received carboplatin day 1 and ABI-007 on days 1 and 8
every 21 days. For patients enrolled in the pharmacokinetic portion of the trial, in the first
cycle of therapy, ABI-007 was infused followed by carboplatin 30 min later, and vice versa
during the second cycle.
Study drugs
ABI-007 (Abraxane) was supplied by the manufacturer and carboplatin (Paraplatin) was
obtained through commercial sources. The dose of ABI-007 was calculated using the
patient’s body surface area (BSA), with the maximum BSA of 2.0. The dose of carboplatin
was fixed at an area under the curve (AUC) of six using the Cockcroft-Gault equation to
estimate the glomerular filtration rate, and the Calvert equation to calculate the carboplatin
dose [13]. Patients received antiemetic therapy with ondansteron and dexamethasone before
each treatment with carboplatin and ABI-007 on day 1, and received dexamethasone 4 mg
twice daily for 3 days following the day 1 treatment unless contraindicated. On treatment
arms B and C patients did not receive antiemetic therapy prior to treatment with single agent
ABI-007 on days 8 or 15. No premedications for hypersensitivity were given and the
prophylactic use of filgrastim was prohibited during the first cycle. Patients who
experienced a dose-limiting toxicity could continue on treatment at a reduced ABI-007 dose
level at the discretion of the treating physician.
Dose escalation
Three patients were treated at the initial dose level for each treatment group, and if no
cycle-1 dose-limiting toxicities were observed, three additional patients were treated at the
next dose level. If one of three initial patients experienced a dose-limiting toxicity at any
given dose level, three additional patients were treated at that same dose. If a dose-limiting
toxicity occurred in at least two patients at any dose level, dose escalation was halted, and
the next three patients enrolled onto that treatment group were treated at the next lower dose
level. The MTD and the recommended treatment dose for each schedule were defined as the
highest dose level at which fewer than two of six patients experienced a dose-limiting
toxicity in cycle 1. Toxicity was assessed using the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0.
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Dose-limiting toxicities were assessed after the first cycle, and were defined as grade ≥ 3
nonhematologic toxicity, grade 4 anemia or thrombocytopenia, or grade 4 neutropenia
lasting ≥7 days or associated with fever. Patients were required to have all treatment-related
toxicity from the previous cycle resolve to baseline or NCI CTCAE grade ≤ 1 before
initiating the second cycle of therapy. A >2-week treatment delay of initiating the second
cycle of chemotherapy was considered a dose-limiting toxicity. For patients receiving
weekly treatment of ABI-007, treatment was omitted for patients with ANC <1.5 × 109 L−1
or a platelet count <100 × 109 L−1. Patients in group B who had myelosuppression that
required omission of two of the three weekly treatments, and patients in group C who had
myelosuppression that required omission of one of the two weekly treatments were
considered to have had a dose-limiting toxicity.
Pharmacokinetic analysis
Whole blood was obtained from an indwelling venous catheter in the arm contralateral to the
arm into which the drug was infused and samples were drawn at 11 prespecified time points
(baseline, end of ABI-007 infusion, 1, 2, 3, 4, 5, 6, 20–28, 40–48, and 70–78 h after
ABI-007 infusion). Approximately 5 mL of whole blood was drawn in sodium EDTA-
containing tubes and an additional 7 mL of whole blood was drawn into heparinized tubes
for each time point; the heparinized sample was centrifuged at 1,000×g for 10 min at 4°C
and aliquots of plasma were collected and stored with the whole blood at −80°C until
analysis. Paclitaxel was extracted from 10 µL whole blood and plasma samples using
protein precipitation with methanol containing docetaxel as the internal standard (5:1
methanol:sample). Paclitaxel concentration was quantitated using high-performance liquid
chromatography, and detection was performed by triple quad mass-spectrometry using
electrospray atmospheric pressure ionization. (SCIEX API 4000, Applied Biosystems
Concord, Ontario, Canada). The lower limit of quantitation was 10 nM, and the range for the
standard curve was 10–30,000 nM. Quality controls were back calculated to within 15% of
nominal.
Individual paclitaxel whole blood concentrations using WinNonlin 4.0 (Pharsight Corp.,
Mountain View, CA) were used to estimate maximum plasma concentration (Cmax), area
under the concentration–time cure through infinity (AUC∞), area under the concentration
time curve through the last measurable time point (AUCt); terminal half-life [t1/2], whole
blood clearance (Cl), and apparent steady-state volume of distribution (Vss). The AUC was
calculated using the Log-linear trapezoidal method. Vss was estimated from the product of
mean residence time and Cl.
Statistical analysis
All pharmacokinetic data were log-transformed before analysis and pharmacokinetic
parameters are reported as geometric mean and coefficient of variation. For AUC, data are
reported as a ratio of log-transformed data and 90% confidence interval. A 2-tailed, paired
students’ t test was used to test for significant differences between cycles. The correlation
between AUC and ANC nadir was compared using Pearson’s correlation coefficient.
Significance was set at P < 0.05.
Results
Patients
Forty-seven patients were enrolled on the trial, and 41 patients were treated. Most patients
had either lung cancer or melanoma, were heavily pretreated, and most patients were white
(Table 1). The dose levels of ABI-007, number of patients, and number of cycles received
for each dose level are included in the toxicity tables (Tables 2, 3).
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Determination of the maximum tolerated dose
In group A, no dose-limiting toxicities were observed at the first three dose levels (220, 260,
or 300 mg/m2). At 340 mg/m2, one of the first three patients developed a dose-limiting
toxicity (grade 3 myalgias/arthralgias) so the cohort was expanded. The first two patients of
the expanded cohort were enrolled simultaneously, and experienced a dose-limiting toxicity
(grade 3 nausea/vomiting and hyperglycemia (n = 1); and grade 3 nonneutropenic infection
and nausea/vomiting (n = 1). In the interim, the third patient, who had not experienced
significant toxicity prior to the expansion, experienced a 2-week treatment delay in initiating
the second cycle of chemotherapy related to thrombocytopenia (platelet count 75–100 × 109
L−1). Three additional patients were enrolled at the previous dose level, 300 mg/m2, and
none experienced a dose-limiting toxicity.
In group B, no dose-limiting toxicities were observed in the first three patients at 100 mg/
m2. At the next dose level, 125 mg/m2, one of the first three patients experienced a dose-
limiting toxicity (grade 3 dehydration and grade 4 thrombocytopenia). Three additional
patients were enrolled, and one patient had a dose-limiting toxicity (grade 3
thrombocytopenia requiring the omission of day-8 and day-15 treatment). An additional
three patients were enrolled at the previous dose level, 100 mg/m2. One patient received
treatment on day 8 with grade 3 thrombocytopenia in violation of the treatment protocol and
was considered nonevaluable for determination of the MTD. Three additional patients did
not experience a dose-limiting toxicity; however, two of the six evaluable patients had
omission of the day-15 treatment related to myelosuppression [grade 3 neutropenia (n = 1);
and grade 3 neutropenia/thrombocytopenia (n = 1)].
In group C, one of the first three patients experienced a dose-limiting toxicity (grade 4
thrombocytopenia), and four additional patients were enrolled, none of whom experienced a
dose-limiting toxicity. At the next dose level, one of the first three patients, and the fourth
patient experienced a dose-limiting toxicity [grade 3 infection (n = 1); grade 3 febrile
neutropenia/grade 4 thrombocytopenia (n = 1)].
The primary dose-limiting toxicity was myelosuppression, and the MTD of ABI-007 in
combination with full dose carboplatin (AUC = 6) was 300, 100, and 125 mg/m2 for groups
A, B, and C, respectively.
Toxicities
Hematologic toxicity—All the hematologic toxicity is summarized in Table 2. Fourteen
patients experienced grade 3 or 4 neutropenia, and three patients experienced grade 3 febrile
neutropenia. Twelve patients developed grade 3 or 4 thrombocytopenia, and three patients
required platelet transfusion for an absolute platelet count <10 × 109 L−1 (1 patient) or <25
× 109 L−1 with mucocutaneous bleeding (2 patients). Five patients developed grade 3
anemia, 13 patients required transfusion of packed red blood cells, and 14 patients required
erythropoietin growth factor support.
Nonhematologic toxicity—All the non-hematologic toxicities consisted of mylagias,
nausea, vomiting, fatigue and alopecia, and toxicities for all cycles are summarized in Table
3. Five patients developed grade 2 and three patients developed grade 3 sensory neuropathy.
Most of these patients had resolution of the neuropathy or return to baseline or grade ≤ 1
with discontinuation of the drug; however, one patient had persistent grade 3 neuropathy for
6 months. Six of the eight patients who developed ≥2 grade neuropathy had previous
treatment with a drug known to cause sensory neuropathy (i.e., oxaliplatin, carboplatin,
interferon, docetaxel, or solvent-based paclitaxel).
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Thirty-seven patients were evaluable for response according to RECIST after two cycles of
therapy. The best response for the patient is reported, and patients who experienced stable
disease or response did not undergo radiological confirmation of response. Responses were
noted in 12 patients (melanoma, n = 3; NSCLC, n = 3; and one each for small cell lung
cancer (SCLC), breast, pancreatic, bladder, esophageal, and cancer of unknown primary).
Twelve additional patients had stable disease (NSCLC, n = 6; melanoma, n = 3, SCLC, n =
2, breast, n = 1). One additional patient with adenocarcinoma of unknown primary did not
have evaluable disease by RECIST, but had an elevated of CA-125 that had correlated with
disease progression and response in the past. At baseline, this patient’s CA-125 value was
503 U/mL, and declined to normal (15.2 U/mL) after three cycles, and remained within
normal limits for nine months. A patient with prostate cancer had radiographically stable
disease; however, his prostate-specific antigen concentration (PSA) increased from a
baseline of 1,810–2,760 ng/mL after two cycles, and was classified as progressive disease.
Pharmacokinetic results
Fifteen patients completed the first two cycles of chemotherapy, and 14 were evaluable for
analysis. The pharmacokinetic parameters are shown in Table 4. The point estimate of the
log transformed AUC ratio between cycle 1 and cycle 2 was 1.01 with a coefficient variance
of 1.604. The AUC of ABI-007 was not significantly different between cycle 1 and cycle 2
(P = 0.20) (Fig. 1). No difference was seen between the ANC nadir between cycle 1 and
cycle 2 (2.2 × 109 L−1 vs. 1.9 × 109 L−1, respectively; R2 = 0.17, P = 0.33).
Discussion
This phase I trial was designed to evaluate the feasibility of administering ABI-007 in
combination in carboplatin using three different ABI-007 treatment schedules. In group A,
we were able to combine ABI-007 at 300 mg/m2 every 21 days with standard-dose
carboplatin. This ABI-007 dose was the MTD reported in the single-agent, phase I trial and
the dose used in a previously reported single agent phase II trial [14,15] This dose is higher
than that achieved with solvent-based paclitaxel, which is typically combined at a dose of
175–225 mg/m2 with carboplatin AUC = 6 [6,16,17].
The MTD seen with single-agent ABI-007 on the treatment schedule evaluated in group B
(ABI-007 on days 1,8, and 15 every 28 days) was 100 mg/m2 in the heavily pretreated
patients and 150 mg/m2 in the less heavily pretreated patients [18]. The MTD of ABI-007 in
combination with carboplatin in of group B corresponds to the MTD in the heavily
pretreated population of the single agent ABI-007 on the same schedule. We did not
prospectively stratify patients based on their previous therapy; however, five of the seven
patients at the 100 mg/m2 dose level, and the two patients who experienced dose-limiting
toxicities at the 125 mg/m2 dose would be considered as heavily pretreated using the criteria
in the single-agent phase I study [18].
Two heavily pretreated patients at the 100 mg/m2 required omission of the day-15 treatment
because of myelosuppression [grade 3 neutropenia (n = 1); and grade 3 neutropenia/
thrombocytopenia (n = 1)]. Treatment in a chemotherapy naïve patient population may result
in a lower rate of myelosuppresion and improve the delivery of the day 15 chemotherapy.
Preliminary data from two phase II trials of carboplatin (AUC = 6) and ABI-007 100 mg/m2
on the same treatment schedule have demonstrated an acceptable toxicity profile [19,20].
ABI-007 has not been investigated as a single agent on the treatment schedule of days 1, 8
every 21 days as used in group C. The schedule of carboplatin every 3 weeks may be
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advantageous in diseases that respond to carboplatin-based therapy. This schedule is being
further investigated as part of an ongoing phase II trial in NSCLC.
The most frequent toxicities seen in this study were myelosuppression, sensory neuropathy,
myalgias/athralgias, nausea, vomiting, and alopecia, which are the toxicities typically seen
with carboplatin and solvent-based paclitaxel [21]. The incidence sensory neuropathy is
higher with ABI-007 than with solvent-based paclitaxel [5]. The incidence of neuropathy is
known to increase significantly after four cycles of carboplatin and solvent-based paclitaxel
and the incidence of sensory neuropathy with carboplatin and ABI-007 may be cumulative
as well [21]. Given the small size of this study, the differences in ABI-007 doses and
number of cycles, and prior therapy patients received, it is difficult to determine if there was
a relationship between the dose of ABI-007 and the development of neuropathy in this
study.
The optimal method of dosing of palliative chemotherapy in patients with a significantly
elevated BSA is controversial. The practice of using a maximum BSA is a debatable;
however, frequently used method to address this clinical situation. This trial used a
maximum BSA of 2.0, and this practice resulted in a ≥10% change in the dose of ABI-007
in five patients. In reviewing the toxicity data and the dose escalation process in this trial the
use of a maximum BSA of 2.0 did not influence the determination of the MTD.
The infusion sequence did not affect the pharmacokinetics of ABI-007, and the ANC nadir.
This finding is suggests that alteration of the sequence of infusion of ABI-007 and
carboplatin may not result in a clinically relevant outcome such as seen with cisplatin and
solvent-based paclitaxel [9]. Our results are consistent with previous data that has shown
that sequence of infusion of carboplatin and solvent-based paclitaxel did not impact the
pharmacokinetics of solvent-based paclitaxel or the degree of neutropenia [10,11].
In conclusion, in this heavily pretreated population of refractory cancer patients, the
combination of ABI-007 and carboplatin was well tolerated with an acceptable toxicity
profile on all three schedules.
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patients, filled triangle weekly patients, P = 0.20 for all patients)
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Table 1
Patient characteristics at baseline
Characteristic
 Total no. patients 41
Age (years)
 Median (range) 58 (32–75)
ECOG Performance Status
 0 16 (39%)
 1 22 (54%)
 2 3 (7%)
Sex
 Men 21 (51%)
 Women 20 (49%)
Race
 White 32 (78%)
 Black 8 (20%)
 Latino 1 (2%)
Median number previous therapies 3
Malignancy
 Non-small-cell lung 12 (29%)
 Melanoma 10 (24%)
 Small-cell lung 3 (7%)
 Breasta 3 (7%)
 Soft tissue sarcoma 3 (7%)
 Unknown primary 2 (5%)
 Gastric 2 (5%)
 Otherb 6 (10%)
ECOG, Eastern Cooperative Oncology Group
a
One patient with breast cancer had phyllodes tumor
b
One each: bladder, colorectal, esophageal, pancreatic, penile, prostate
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